基因代理的白介素-6受体抑制与COVID-19及肺炎的相反关联
该研究探讨基因代理的白介素-6受体(IL6R)抑制与COVID-19和肺炎风险的关联。IL-6是重症COVID-19炎症反应的核心细胞因子,IL6R抑制被考虑用于治疗COVID-19,但可能增加肺炎风险,需警惕其应用。
要点
- IL6R抑制可能对COVID-19有益但增加肺炎风险,需权衡。
- 重症COVID-19存在IL-6等炎症因子升高,免疫调节是治疗方向。
- 地塞米松在需要呼吸支持的住院COVID-19患者中降低28天死亡率。
核心结论
- 基因代理的IL6R抑制与COVID-19和肺炎存在相反关联,提示IL6R阻断用于治疗COVID-19时需警惕肺炎风险。
研究设计与样本
- 原文未报告具体研究设计与样本量。
主要发现
- 一项荟萃分析显示,复杂COVID-19患者的平均IL-6浓度是非复杂患者的2.9倍。
- RECOVERY试验发现,地塞米松使随机化时接受有创机械通气或单纯氧疗的住院COVID-19患者28天死亡率降低,但未接受呼吸支持者无此获益。
临床怎么用
- 应用IL6R抑制治疗COVID-19时,应警惕并监测肺炎风险。
- 重症COVID-19可考虑免疫调节治疗,但需根据呼吸支持状态评估获益人群。
局限性
- 原文未报告具体研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Respiratory disease is a main feature of severe COVID-19, and the potential of IL-6 receptor blockade to increase risk of pneumonia warrants vigilance and caution in its application to treat COVID-19 https://bit.ly/34Y8Ner The inflammatory cytokine interleukin-6 (IL-6) is central to orchestrating the immune system [1]. The pathophysiological process underlying severe coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2, consists of an exaggerated host immune response and elevated circulating levels of inflammatory cytokines, including IL-6 [2, 3]. As such, immunomodulatory agents are being investigated for the treatment of COVID-19. Glucocorticoids may limit inflammation-mediated lung injury in patients with severe COVID-19, and consequently reduce progression to respiratory failure and death. The RECOVERY trial found that administration of dexamethasone resulted in lower 28-day mortality among hospitalised COVID-19 patients who were receiving either invasive mechanical ventilation or oxygen alone at randomisation, but not among those who were not receiving any respiratory support [4]. IL-6 receptor (IL6R) inhibition may represent another potential immunomodulatory strategy for treating COVID-19 [5, 6], and a recent meta-analysis of mean IL-6 concentrations demonstrated 2.9-fold higher levels in patients with complicated COVID-19 compared with patients with non-complicated disease [7].
引用
- Larsson SC, Burgess S, Gill D, et al. Genetically proxied interleukin-6 receptor inhibition: opposing associations with COVID-19 and pneumonia. Eur Respir J. 2021. PMID: 33214204. doi:10.1183/13993003.03545-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。